Available immunotherapies for relapsed or refractory ALL include Blinatumomab Inotuzumab ozogamicin Tisagenlecleucel Blinatumomab, a biospecific CD19-directed CD3 T-cell engager, prolongs overall survival for children and adults with relapsed or refractory B-cell precursor ALL, whether Ph+ or Ph-.